It hasn't been a great 2021 so far for the CSL (ASX:CSL) share price

What's been impacting the biotech giant's shares this years?

| More on:
a doctor with stethoscope around neck sits as a computer with head in hand, looking despondent.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has remained relatively flat when compared to the beginning of the year, up less than 3%. In comparison, the S&P/ASX 200 Index (ASX: XJO) is up almost 14% year to date.

During Wednesday's trading session, CSL shares continued to move largely sideways, sliding 0.69% to $292.28.

How is CSL comparing against the ASX 200?

On average, the ASX 200 has returned 6.50% per annum to shareholders over the last 5 years, and 5.78% per annum over its 10-year chart. The most significant gain was achieved in 2019 when the index grew 23.02%. On the other hand, the biggest fall came in 2011, when it lost 10.84%. Surprisingly, despite the pandemic-induced crash in 2020, that year did not deliver the biggest losses thanks to the ASX 200's sharp rebound.

Why is it worth looking at the 5-year and 10-year gains of the ASX 200? The reason is that, historically, CSL shares have outperformed the ASX 200 by a significant margin. Over the past 5 years, the company has delivered a 155% return. When looking at the last 10 years, the CSL share price has jumped by around 930% over the period.

What's been affecting the CSL share price lately?

CSL has been marred with plasma collection issues stemming from early 2020 when COVID-19 arrived on the world stage. Governments around the world enforced restrictions on passenger movements and closed down international borders in an effort to help curb the spiralling outbreak.

This was particularly bad news for CSL as it relies on the plasma from blood donors to make its life-saving medicines.

The company last provided an update in March advising that December 2020 plasma volumes were sitting at around 80% of December 2019 levels.

While current plasma levels are expected to eventually bounce back, no one can be certain exactly when this will occur. This uncertain environment has likely weighed on investor optimism, sending CSL shares in circles over the past 18 months.

The most recent broker note on CSL came from Macquarie yesterday. The broker cut its 12-month price target for CSL shares by 1.3% to $308.00. Based on the current CSL share price, this implies an upside of around 5% to investors.

CSL share price snapshot

Over the course of the past 12 months, CSL shares have taken investors on a rollercoaster ride, but are up just 5.08%. The company's shares are currently sitting just above the middle of their 52-week range of $242.00 to $320.42.

On valuation grounds, CSL is the third-largest company on the ASX with a market capitalisation of roughly $133 billion.

Motley Fool contributor Aaron Teboneras owns shares of CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia owns shares of and has recommended Macquarie Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

drug capsule opening up to reveal dollar signs signifying rising asx share price
Healthcare Shares

3 ASX healthcare shares going gangbusters on Thursday

Investors are sending these ASX healthcare stocks soaring today. But why?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Is it time to cash in on Sigma shares?

Shares have extended after the Chemist Warehouse merger.

Read more »

Person holding Australian dollar notes, symbolising dividends.
Healthcare Shares

Buy this ASX 200 share that is swimming in cash

Bell Potter sees potentially big returns on offer from this cashed-up stock.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Are CSL shares a buy after the biotech's FY25 forecasts?

Brokers continue to weigh in.

Read more »

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Are Wesfarmers or Sigma shares a better buy in the pharmacy arena?

These two stocks are both leaders in the industry.

Read more »

A young man goes over his finances and investment portfolio at home.
Healthcare Shares

Down 20%, is the NIB share price undervalued?

Here's what Goldman Sachs is saying about this blue chip stock.

Read more »

four excited doctors with their hands in the air
Healthcare Shares

Sigma Healthcare shares rocket 39% on Chemist Warehouse merger approval

The ACCC doesn't believe the company's merger with Chemist Warehouse will lessen competition.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

ASX 200 healthcare stock rockets on $75 million news

This marks another positive step for the company.

Read more »